Recruiting
Phase 1

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Sponsor:

Louis Messina

Code:

NCT04800692

Conditions

Claudication, Intermittent

Peripheral Artery Disease

Peripheral Vascular Diseases

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Tetrahydrobiopterin 10 mg/kg

Tetrahydrobiopterin 20 mg/kg

L-Ascorbate

L-Arginine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-30. This information was provided to ClinicalTrials.gov by Louis Messina on 2023-11-18.